MSD’s Keytruda in combination with Pfizer's Inlyta has been found to reduce the risk of death by nearly half in patients with advanced renal cell carcinoma (RCC).Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.